Skip to main content
Cary Harding, MD, Medical Genetics, Portland, OR

CaryOwenHardingMD

Medical Genetics • Portland, OR

Clinical Biochemical Genetics, Clinical Genetics

Associate Professor, Molecular & Medical Genetics, Oregon Health and Science University School of Medicine

Join to view full profile

Dr. Harding is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Harding's full profile

Already have an account?

  • Office

    707 SW Gaines St
    Portland, OR 97239
    Phone+1 503-494-7859
    Fax+1 503-494-4447

Education & Training

  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 1987 - 1990
  • University of Washington School of Medicine
    University of Washington School of MedicineClass of 1987

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 1999 - 2025
  • ID State Medical License
    ID State Medical License 2004 - 2024
  • WI State Medical License
    WI State Medical License 1988 - 1999
  • American Board of Medical Genetics and Genomics Clinical Biochemical Genetics
  • American Board of Medical Genetics and Genomics Clinical Genetics and Genomics

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • BioMarin Pharmaceutical : , Pioneer in Rare Disease Treatments for Phenylketonuria, Receives FDA Approval of Label Expansion
    BioMarin Pharmaceutical : , Pioneer in Rare Disease Treatments for Phenylketonuria, Receives FDA Approval of Label ExpansionOctober 15th, 2020
  • FDA Approves New Drug Tested at OHSU for Phenylketonuria, or PKU - Portland Business Journal
    FDA Approves New Drug Tested at OHSU for Phenylketonuria, or PKU - Portland Business JournalMay 25th, 2018
  • BioMarin Sinks Despite Meeting Primary Endpoint
    BioMarin Sinks Despite Meeting Primary EndpointMarch 21st, 2016

Grant Support

  • Augmented Phenylalanine Clearance By Muscles As Novel Therapy For PhenylketonuriaEunice Kennedy Shriver National Institute Of Child Health &Human Development2009–2012
  • AAV2/8 Vector-Mediated Liver Gene Therapy For Phenylketonuria (PKU)National Institute Of Diabetes And Digestive And Kidney Diseases2007–2009
  • Liver Gene Therapy For Murine Phenyketonuria (PKU)National Institute Of Diabetes And Digestive And Kidney Diseases2006
  • Intravenous Non-Viral Gene Therapy For Phenylketonuria (PKU)National Institute Of Diabetes And Digestive And Kidney Diseases2006
  • Stem Cell-Mediated Liver Repopulation For Murine PKUNational Heart, Lung, And Blood Institute2005–2006
  • DHA Triglyceride Supplementation In Lchadd PatientsNational Center For Research Resources2004–2005
  • Metabolic Engineering As Therapy For Murine PKUNational Institute Of Diabetes And Digestive And Kidney Diseases2001–2002
  • Docosahexaenoic Acid Triglyceride Supplementation In LchaddNational Center For Research Resources2000–2002
  • DHA Triglyceride Supplementation In Long Chain Dehydrogenase Deficiency (LCHADD)National Center For Research Resources1998–2002
  • Heterologous Gene Therapy For MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2000
  • Aav-Mediated Gene Therapy--Inborn Errors Of MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1999
  • Heterologous Gene Therapy For MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1999

Dr. Cary Harding, Dr. Cary Harding, MD, Dr. C Harding, Dr. Cary Owen Harding